




PHARMACEUTICAL 2023

NovaBay Pharmaceuticals Inc.
Rank 266 of 446





PHARMACEUTICAL 2023

NovaBay Pharmaceuticals Inc.
Rank 266 of 446



The relative strengths and weaknesses of NovaBay Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NovaBay Pharmaceuticals Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 92% points. The greatest weakness of NovaBay Pharmaceuticals Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 112% points.

The company's Economic Capital Ratio, given in the ranking table, is 34%, being 9.6% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	11,332
Cost of Goods Sold	6,623
Intangible Assets	2,628
Liabilities, Current	4,257
Liabilities, Non-Current	1,588
Other Assets	2,320
Other Compr. Net Income	0
Other Expenses	14,535
Other Liabilities	0
Other Net Income	0
Other Revenues	14,404
Property and Equipment	119
Research and Development	174
Selling, General and Administrative Expense	7,489

Output Variable	Value in 1000 USD
Assets	16,399
Liabilities	5,845
Expenses	28,821
Revenues	14,404
Stockholders Equity	10,554
Net Income	-14,417
Comprehensive Net Income	-14,417
Economic Capital Ratio	34%